12 小时
Asian News International on MSNAkums Drugs and Pharmaceuticals announces robust Q3 FY 25 results with 12% Adj EBITDA and ...Operating performance of the company was robust with overall Adj EBITDA growing 12% YoY and Adj PAT growing 15% YoY driven by better profitability in our core CDMO segment. The EBITDA improvement ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果